中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
3期
280-281
,共2页
魏兵%李奇玉%蒋静%李薇%唐英
魏兵%李奇玉%蔣靜%李薇%唐英
위병%리기옥%장정%리미%당영
哮喘%孟鲁司特%儿童
哮喘%孟魯司特%兒童
효천%맹로사특%인동
Asthma%Montelukast%Children
目的 观察孟鲁司特在2~5岁儿童哮喘防治中的效果.方法 66例2~5岁学龄前哮喘患儿完全随机分为治疗组与对照组,各33例.治疗组在常规治疗的基础上加用孟鲁司特,对照组给予辅舒酮气雾吸入,疗程均3个月.结果 急性发作期治疗组疗效优于对照组[症状缓解时间:(4.26±1.57)d比(5.83±1.62)d;肺部体征消失时间:(3.84±1.31)d比(5.25±1.12)d;P<0.01];急性发作期治疗后患儿外周血嗜酸粒细胞计数治疗组较对照组降低[(0.36±0.12)×109/L比(0.51±0.15)×109/L],差异有统计学意义(P<0.05);治疗组较对照组复发次数少、无症状时间长、再次发作的病情轻(均P<0.05).结论 孟鲁司特依从性好,对于2~5岁学龄前儿童轻中度哮喘治疗及预防疗效显著.
目的 觀察孟魯司特在2~5歲兒童哮喘防治中的效果.方法 66例2~5歲學齡前哮喘患兒完全隨機分為治療組與對照組,各33例.治療組在常規治療的基礎上加用孟魯司特,對照組給予輔舒酮氣霧吸入,療程均3箇月.結果 急性髮作期治療組療效優于對照組[癥狀緩解時間:(4.26±1.57)d比(5.83±1.62)d;肺部體徵消失時間:(3.84±1.31)d比(5.25±1.12)d;P<0.01];急性髮作期治療後患兒外週血嗜痠粒細胞計數治療組較對照組降低[(0.36±0.12)×109/L比(0.51±0.15)×109/L],差異有統計學意義(P<0.05);治療組較對照組複髮次數少、無癥狀時間長、再次髮作的病情輕(均P<0.05).結論 孟魯司特依從性好,對于2~5歲學齡前兒童輕中度哮喘治療及預防療效顯著.
목적 관찰맹로사특재2~5세인동효천방치중적효과.방법 66례2~5세학령전효천환인완전수궤분위치료조여대조조,각33례.치료조재상규치료적기출상가용맹로사특,대조조급여보서동기무흡입,료정균3개월.결과 급성발작기치료조료효우우대조조[증상완해시간:(4.26±1.57)d비(5.83±1.62)d;폐부체정소실시간:(3.84±1.31)d비(5.25±1.12)d;P<0.01];급성발작기치료후환인외주혈기산립세포계수치료조교대조조강저[(0.36±0.12)×109/L비(0.51±0.15)×109/L],차이유통계학의의(P<0.05);치료조교대조조복발차수소、무증상시간장、재차발작적병정경(균P<0.05).결론 맹로사특의종성호,대우2~5세학령전인동경중도효천치료급예방료효현저.
Objective To explore the curative and preventive effect of montelukast in 2-5 years old asthmatic children. Motheds Sixty-six cases were randomly assigned as group A (were treated with fluticasone propionate inhalation) and group B (were administrated orally at montelukast). They were treated with routine treatment.The total course of two groups were three month. Results The curative effect of group B was significantly better than that of group A in acute attack of asthmatic children. The relapse, sympto-matic stage, relapse pathocure of group B were significantly better than that of group A. There was significant difference between treatment before and treatment after (symptoms disappearing) that EC of asthmatic children( P <0.05 ), There were some differences between group B ahd group A that there were less times that symptoms appeared after treatment. It was a long time that symptoms disappeared. Conclusion The clinical experiments show that montelukast has dramatic efficacy for the 2-5 years old children with low-grade or moderate asthma without any side effects.